Welcome to our dedicated page for Invizyne Technologies SEC filings (Ticker: IZTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IZTC SEC filings page on Stock Titan offers access to historical regulatory documents for Invizyne Technologies, Inc., which has since changed its corporate name to eXoZymes Inc. and now lists its common stock on the Nasdaq Capital Market under the ticker EXOZ. These filings provide a record of how the company reported its activities, governance, and material events while its shares were associated with the IZTC symbol.
Among the key documents are Form 8-K current reports, where the company discloses material events such as participation in major research and development initiatives. For example, an 8-K describes eXoZymes Inc. being selected to participate in the National Science Foundation-funded Meta-PURE initiative under the CFIRE program, outlining its role in developing a cell-free ATP-generating module to support cell-free biomanufacturing across various applications.
Investors can also review the company’s definitive proxy statement on Schedule DEF 14A, which details matters submitted to shareholders at the annual meeting, including director elections, advisory votes on executive compensation, approval of a performance equity plan, and ratification of the independent registered public accounting firm. The proxy statement further explains voting procedures, board structure, and certain compensation and governance policies.
Through Stock Titan, these historical IZTC filings are paired with AI-powered tools that help readers interpret complex sections, highlight key items such as compensation arrangements and equity plans, and quickly locate information about corporate actions. Users researching the transition from Invizyne Technologies, Inc. (IZTC) to eXoZymes Inc. (EXOZ) can rely on this page to follow the company’s regulatory trail and better understand how its cell-free enzyme-based biomanufacturing business is reflected in official SEC disclosures.
eXoZymes Inc. reported no revenue for the quarter and a six-month net loss of $4,216,707, or $0.50 per share, driven by increased R&D and G&A spending. Cash and cash equivalents totaled $6,985,858 at June 30, 2025, down from $9.72 million at year-end 2024, and working capital was approximately $6,314,087. The company offset research costs with government grants but grant receivables fell to $257,407.
The company raised net IPO proceeds of $15,206,543 in November 2024 and used funds for operations and debt repayment. Management disclosed substantial doubt about going concern and identified a material weakness in internal controls. Subsequent events include a July 1, 2025 NSF-related industrial partnership award (company share $3.0M) and board approval of an expanded 2025 equity incentive plan.
Invizyne Technologies Inc. ("IZTC") has filed Amendment No. 1 to its definitive proxy statement (Form DEFR14A) to correct the proxy card for Proposal 1, the election of directors. The updated card now offers shareholders the standard choices of "For All," "Withhold All," or "For All Except," and explains how to withhold authority for specific nominees.
The company notes that proxy materials have not yet been distributed, so investors will receive only the corrected version, avoiding the need for multiple or color-coded cards. No other proposals, financial metrics, or strategic items were affected by this administrative update.
eXoZymes Inc. (symbol: IZTC) has filed its Definitive Proxy Statement (Schedule 14A) for the 2025 Annual Meeting of Shareholders. The meeting will be held virtually on July 25, 2025 at 1:00 p.m. Pacific Time via www.virtualshareholdermeeting.com/EXOZ2025; in-person attendance is not permitted. Shareholders of record at the close of business on June 9, 2025 are entitled to vote, and proxy materials will be mailed or otherwise made available on or about June 20, 2025.
The proxy lists five voting items:
- Proposal 1: Election of six directors to serve until the 2026 AGM.
- Proposal 2: Non-binding advisory vote on 2025 executive compensation (say-on-pay).
- Proposal 3: Advisory vote on the frequency of future say-on-pay resolutions, with the Board favoring a three-year cycle.
- Proposal 4: Approval of the new 2025 Performance Equity Plan.
- Proposal 5: Ratification of RBSM LLP as independent registered public accounting firm for FY 2025.
The Board of Directors recommends a “FOR” vote on all proposals, including the adoption of the equity plan and three-year say-on-pay frequency. No additional matters are expected, but any other proper business may be transacted.
The filing is routine in nature, with no financial performance data, mergers, or capital-raising activities disclosed. Key governance items include detailed information on board structure, risk oversight, director independence, compensation philosophy, and a clawback policy.
FAQ
What is the current stock price of Invizyne Technologies (IZTC)?
What is the market cap of Invizyne Technologies (IZTC)?
